Let’s compare to my “best-case” simplified list posted in April:
(Latest guidance from lake in bold in brackets)
I said (20/04/2023):
Afaict, even a 10ktpa plant will likely take, best case:
-ESIA report submission: late 2023 (Q1 2024)
-Govt review, consultation, etc etc and the issue of permits: late 2024 (Q1 2025)
-Funding secured, FID: end 2024 (Q4 2024 & Q1 2025)
-FEED and detailed design: if paralleled, end 2024 (Q3 2024; FEED)
-Construction: 2025 + 2026 (2025 + 2026 + H1 2027)
-Commissioning and steady-state production: mid 2027 (H2 2027?)
-Ramp up to (near) nameplate: late 2027. (Q4 2027-Q3 2028; 25ktpa)
—-
I’d call that a dart pretty damn close to the bulls eye.
Still doesn’t account for inevitable issues and hiccups along the way. Add 20-50% imo, assuming no dealbreakers, that is.
dyor
- Forums
- ASX - By Stock
- LKE
- LKE towards TOP-5
LKE towards TOP-5, page-23441
-
- There are more pages in this discussion • 686 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add LKE (ASX) to my watchlist
|
|||||
Last
3.8¢ |
Change
-0.002(5.00%) |
Mkt cap ! $63.40M |
Open | High | Low | Value | Volume |
4.0¢ | 4.1¢ | 3.8¢ | $230.1K | 5.879M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
45 | 4289511 | 3.8¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
3.9¢ | 160348 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
44 | 4189511 | 0.038 |
29 | 2802808 | 0.037 |
25 | 1850530 | 0.036 |
30 | 3837186 | 0.035 |
6 | 643852 | 0.034 |
Price($) | Vol. | No. |
---|---|---|
0.039 | 160348 | 3 |
0.040 | 773696 | 12 |
0.041 | 662845 | 7 |
0.042 | 687425 | 8 |
0.043 | 478131 | 4 |
Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
Featured News
LKE (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online